Acute phase proteins in salmonids: evolutionary analyses and acute phase response
1997 · The Journal of Immunology · 169 citations
https://doi.org/10.4049/jimmunol.158.1.384
C
Clarissa Uhlar
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
69
Papers
7.6K
Citations
30
h-index
41
i10-index
Clarissa Uhlar is an academic researcher. The author has contributed to research in topics: Multiple Myeloma Research and Treatments & Monoclonal and Polyclonal Antibodies Research & Chronic Lymphocytic Leukemia Research. The author has an h-index of 30, co-authored 59 publications.
Papers by this author
worksA randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma
2011 · British Journal of Cancer · 115 citations
https://doi.org/10.1038/bjc.2011.183
Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1
2023 · Targeted Oncology · 35 citations
https://doi.org/10.1007/s11523-023-00989-z
Expression of a biologically active recombinant mouse IL-1 receptor antagonist and its use in vivo to modulate aspects of the acute phase response
1997 · The Journal of Immunology · 17 citations
https://doi.org/10.4049/jimmunol.159.1.369
Efficacy and Safety of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) With High-Risk (HR) Features: A Subgroup Analysis From the Phase 1/2 MajesTEC-1 Study
2024 · Clinical Lymphoma Myeloma & Leukemia · 1 citations
https://doi.org/10.1016/s2152-2650(24)00951-0
P-089 Impact of COVID-19 on Outcomes With Teclistamab in the Phase 1/2 MajesTEC-1 Study in Patients With Relapsed/Refractory Multiple Myeloma
2024 · Clinical Lymphoma Myeloma & Leukemia · 0 citations
https://doi.org/10.1016/s2152-2650(24)01992-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat